drugset
drugset / Trial / NCT00633048

Study Evaluating the Safety and Tolerability of NSA-789

NCT00633048 ↗

Phase 1 Completed 64 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupDouble-blind

Summary

This is the first time that NSA-789, a new compound being developed for schizophrenia, will be given to humans. Each healthy subject will receive a single dose, except for 8 subjects who will receive 2 doses-- one dose under fasting conditions and one dose after eating food.

Timeline

Start
2008-03
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject NSA-789 Unknown — —

Indications

No indication recorded.